Recent developments in the prognostic use of myocardial perfusion imaging.
Stress myocardial perfusion imaging has become a mainstay in the noninvasive assessment of patients with known or suspected coronary artery disease for several compelling reasons. Radionuclide myocardial perfusion imaging can be performed using a variety of stressors, including exercise, pharmacologic stress (including dipyridamole, adenosine, dobutamine, and arbutamine), or a combination of exercise and pharmacologic stress. The combination of exercise and pharmacologic stress allows an assessment of the patient's exercise tolerance, to be performed while adequately stressing him or her pharmacologically. Radiopharmaceutical choice has been expanded to include not only thallium-201 but also technetium-based imaging agents such as sestamibi and tetrofosmin. The use of technetium imaging agents has recently been enhanced by the ability to assess ventricular function using gated single-photon emission computed tomography (SPECT) imaging techniques. Finally, the ability to provide prognostic information in the same patients has led to incremental clinical use.
Mansoor
M R
MR
Division of Cardiology, Hartford Hospital, CT 06102-5037, USA.
Heller
G V
GV
D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000503:physiopathology; D005080:Exercise Test; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000503:physiopathology; D010477:Perfusion; D011379:Prognosis; D011875:Radionuclide Angiography; D012680:Sensitivity and Specificity; D017256:Technetium Tc 99m Sestamibi; D015899:Tomography, Emission-Computed, Single-Photon
D017256:Technetium Tc 99m Sestamibi